Skip to main content
. 2023 Feb 3;12:e44157. doi: 10.2196/44157

Table 2.

Schedule of events of the Brilhar e Transcender study.


Baseline Week 12 Week 24 Week 36 Week 48 or early terminationa HIV seroconversion visit
Eligibility ✓




Measures

Behavioral, partnership, network, and structural measures ✓ ✓ ✓ ✓ ✓ ✓

Adverse events
✓ ✓ ✓ ✓

Social harm
✓ ✓ ✓ ✓

Implementation science: participants



✓

Implementation science: coordination ✓


✓

Implementation science: peer navigators



✓
Laboratory procedures

HIV rapid test ✓ ✓b ✓b ✓b ✓b ✓

CD4+ and CD8+ cell counts ✓c
✓c
✓d ✓

HIV RNA viral load ✓c,d ✓d ✓c,d ✓d ✓c,d ✓

HIV recency testing ✓c



✓

HIV genotyping ✓c



✓

Treponemal syphilis rapid test ✓ ✓ ✓ ✓ ✓

Nontreponemal syphilis (venereal disease research laboratory) testing ✓e ✓e ✓e ✓e ✓e

Hepatitis B rapid test ✓


✓f

Hepatitis B serology ✓g





Hepatitis C rapid test ✓


✓h

Anti–hepatitis C virus ✓i


✓i

Hepatitis C viral load ✓j


✓j

Rectal swab (Chlamydia trachomatis and Neisseria gonorrhoeae) ✓


✓

Dried blood spot (pre-exposure prophylaxis adherence assessment) ✓k ✓k ✓k ✓k ✓k ✓k
Hormone dispensation ✓ ✓ ✓ ✓ ✓ ✓
Medical or psychiatric visit ✓l ✓l ✓l ✓l ✓l

aWithdrawn or discontinued participants before the final visit.

bOnly for participants with a negative HIV test in the previous visit.

cFor all participants living with HIV.

dOnly for HIV-negative participants with recent HIV exposition according to the service guidelines.

eOnly for those with a positive treponemal test result.

fOnly for a negative hepatitis B rapid test result.

gOnly for a positive hepatitis B rapid test result.

hOnly for those with a negative hepatitis C rapid test result.

iOnly for those with a positive hepatitis C rapid test result.

jOnly for those with positive findings on an anti–hepatitis C virus antibody test.

kOnly for participants receiving pre-exposure prophylaxis, except those initiating pre-exposure prophylaxis at the current visit.

lIf clinically indicated.